Compare CCS & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCS | MPLT |
|---|---|---|
| Founded | 2000 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 2014 | 2025 |
| Metric | CCS | MPLT |
|---|---|---|
| Price | $58.09 | $8.19 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 15 |
| Target Price | ★ $78.00 | $26.54 |
| AVG Volume (30 Days) | 173.0K | ★ 352.7K |
| Earning Date | 10-28-2026 | 12-03-2026 |
| Dividend Yield | ★ 2.36% | N/A |
| EPS Growth | N/A | ★ 82.39 |
| EPS | ★ 2.09 | N/A |
| Revenue | ★ $4,117,816,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.43 | N/A |
| P/E Ratio | $25.94 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $47.28 | $7.46 |
| 52 Week High | $76.00 | $40.43 |
| Indicator | CCS | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | 49.56 | 32.55 |
| Support Level | $54.70 | $7.46 |
| Resistance Level | $58.50 | $14.22 |
| Average True Range (ATR) | 2.06 | 0.60 |
| MACD | 0.25 | 0.11 |
| Stochastic Oscillator | 65.51 | 30.68 |
Century Communities Inc is engaged in the development, design, construction, marketing and sale of single-family attached and detached homes. The company builds and sells homes under its Century Communities and Century Complete brands. Its reportable segments for homebuilding operations are: i) West (California and Washington) ii) Mountain (Arizona, Colorado, Nevada and Utah), iii) Texas, iv) Southeast (Florida, Georgia, North Carolina, South Carolina and Tennessee), v) Century Complete (Alabama, Arizona, Florida, Georgia, Indiana, Kentucky, Michigan, North Carolina, and South Carolina). The company's other reportable segments include: Financial Services and Century Living. The company derives the majority of its revenue from the sale of new homes in the Mountain segment.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.